Home > Uncategorized > Darapladib Does Not Reduce MACE in ACS (SOLID-TIMI52)

Darapladib Does Not Reduce MACE in ACS (SOLID-TIMI52)

The Lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor Darapladib did not reduce the risk of major adverse cardiac events in acute coronary syndrome. The paper is available here.

Advertisements
Categories: Uncategorized
  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: